BackTeladoc Health Overview
Teladoc Health Inc

Teladoc Health Target Price

Analysts' average 12-month price target for Teladoc Health is $9.3.

Get informed when a big investor buys or sells

+ Follow

Share Price

$8.8

Average Target Price

$9.305.7% upside

5 analysts in the last 4 months

High: $11 | Low: $7.5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-02Piper SandlerJessica Tassan$1125.1% upsideOpen
2026-11-02UBSKevin Caliendo$92.3% upsideOpen
2026-07-30JefferiesBrian Tanquilut$89% downsideOpen
2026-07-30Evercore ISI$7.514.7% downsideOpen
2026-07-21Canaccord GenuityRichard Close$1125.1% upsideOpen
2026-04-08Evercore ISI$631.8% downsideOpen
2026-03-10Deutsche BankGeorge Hill$1125.1% upsideOpen
2026-02-26Stifel NicolausDavid Grossman$631.8% downsideOpen
2026-02-26Wells FargoStephen Baxter$631.8% downsideOpen
2026-01-16Goldman Sachs$89% downsideOpen
2026-01-09Goldman SachsDavid Roman$92.3% upsideOpen
2025-12-08Barclays$8.53.4% downsideOpen
2025-10-30Stifel NicolausDavid Grossman$89% downsideOpen
2025-07-30Raymond James$1013.7% upsideOpen
2024-12-04Piper SandlerJessica Tassan$1347.8% upsideOpen
2024-10-31CitigroupDaniel Grosslight$1125.1% upsideOpen
2024-10-30Evercore ISIElizabeth Anderson$92.3% upsideOpen
2024-08-06Piper SandlerJessica Tassan$1013.7% upsideOpen
2024-06-11BarclaysSteve Valiquette$20127.4% upsideOpen
2024-05-31JefferiesGlen Santangelo$1013.7% upsideOpen
2024-05-20JefferiesGlen Santangelo$1459.2% upsideOpen
2024-04-05Deutsche BankGeorge Hill$18104.7% upsideOpen
2023-04-12StephensJeff Garro$25184.3% upsideOpen
2022-12-13Citigroup$33275.2% upsideOpen
2022-09-28RBC Capital$35298% upsideOpen
2022-09-27Deutsche Bank$31252.5% upsideOpen
2022-07-31BarclaysSteve Valiquette$42377.5% upsideOpen
2022-07-28Barclays$40354.8% upsideOpen
2022-07-28Oppenheimer$55525.4% upsideOpen
2022-07-28Piper SandlerJessica Tassan$40354.8% upsideOpen
2022-07-28Evercore ISIElizabeth Anderson CFA$28218.4% upsideOpen
2022-06-29Stifel Nicolaus$36309.3% upsideOpen
2022-05-26Goldman Sachs$55525.4% upsideOpen
2022-05-18Piper SandlerJessica Tassan$42377.5% upsideOpen
2022-04-28Craig-Hallum$30241.1% upsideOpen
2022-04-28Canaccord Genuity$50468.5% upsideOpen
2022-04-28Deutsche Bank$44400.3% upsideOpen
2022-04-28RBC Capital$65639.1% upsideOpen
2022-04-28Citigroup$43388.9% upsideOpen
2022-04-28Credit Suisse$35298% upsideOpen
2022-04-28Needham$48445.8% upsideOpen
2022-04-28Leerink Partners$35298% upsideOpen
2022-04-28Leerink PartnersStephanie Davis$35298% upsideOpen
2022-04-28Credit SuisseJonathan Yong$35298% upsideOpen
2022-04-28BarclaysSteven Valiquette$45411.7% upsideOpen
2022-04-28RBC CapitalSean Dodge$65639.1% upsideOpen
2022-04-28Wells FargoStan Berenshteyn$40354.8% upsideOpen
2022-04-28Evercore ISIElizabeth Anderson CFA$30241.1% upsideOpen
2022-04-27Robert W. BairdVikram Kesavabhotla$38332.1% upsideOpen
2022-03-19Cowen & Co.Charles Rhyee$94968.8% upsideOpen

Teladoc Health (TDOC) FAQ

Teladoc Health (TDOC) currently reports a target price of $9.3. Use the charts on this page to explore Teladoc Health's target price history and peer comparisons.

Analysts' average 12-month price target for Teladoc Health is $9.3, about 5.7% upside from the current share price of $8.8. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $9.3, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Teladoc Health, and consider following TDOC for alerts when major investors trade the stock.

Teladoc Health is classified in the Healthcare sector. On target price, it currently shows $9.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TDOC with unrelated industries.